The American Legion Just Backed a Specific Psychedelics Bill, Not Just the Idea
The American Legion has formally backed psychedelic-assisted therapy for veterans with PTSD and traumatic brain injury. Delegates adopted the resolution at the organization’s 107th National Convention in Louisville, and Military.com reported it on September 8. The interesting part is not the endorsement. It is how specific the asks are.
Credentialing standards tend to arrive faster than the approvals that trigger them. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| What passed | A resolution titled Novel Therapeutics for Mental Health Conditions and Traumatic Brain Injury |
| Where | The American Legion’s 107th National Convention in Louisville, Kentucky |
| The bill it backs | S.4220, the Veterans Health Administration Novel Therapeutics Preparedness Act of 2026 |
| What that bill does | Requires the VA to create an Office of Novel Therapeutics and bans step therapy rules |
| The scheduling ask | Move psychedelics from Schedule I to Schedule II to loosen research restrictions |
| The complication | VA officials raised concerns about the bill at an April Senate committee hearing |
What the Resolution Actually Says
The resolution is titled Novel Therapeutics for Mental Health Conditions and Traumatic Brain Injury. It covers veterans and active duty service members.
It asks for three things. Continued research. Responsible implementation. And access to treatments that are not yet approved.
Juliana Mercer, a Marine Corps veteran and past commander of a Montana Legion post, framed it in those terms. Veterans want research, responsible implementation and access to therapies that could change how the hardest mental health conditions get treated.
The Bill It Backs
The resolution supports S.4220, the Veterans Health Administration Novel Therapeutics Preparedness Act of 2026.
Senator Tim Sheehy of Montana introduced it in March. Cosponsors include Ruben Gallego of Arizona, Tammy Duckworth of Illinois and John Boozman of Arkansas. That is two Republicans and two Democrats.
The Senate Veterans Affairs Committee took it up at a hearing on April 29. We covered the earlier legislative push in Congress moves to open the door to psychedelic therapy for veterans.
An Office of Novel Therapeutics
The bill’s central provision would require the VA to stand up an Office of Novel Therapeutics.
That office would develop national clinical standards, readiness plans and workforce credentialing frameworks. It would do this ahead of any FDA approval, for psilocybin, ibogaine and MDMA.
Read that sequence carefully. The bill is not asking the VA to adopt these treatments. It is asking the VA to be ready before it has to decide.
The Step Therapy Provision
One clause deserves more attention than it will get. The bill would prohibit step therapy rules inside the VA for these treatments.
Step therapy requires a patient to fail on older, cheaper options before qualifying for a newer one. It is a standard cost control tool, and it is why treatment-resistant is a formal category in the first place.
Removing it would change who reaches these therapies and how quickly. That is a coverage mechanism, not a research question, and coverage is what ultimately determines scale.
The Rescheduling Ask
The resolution also backs moving psychedelics from Schedule I to Schedule II.
Schedule I means no accepted medical use, and it imposes heavy administrative burden on researchers. Schedule II would loosen that considerably without making anything legal for general use.
Veterans groups have pushed this before, as we covered when veterans pressed for rescheduling to expand research access. What is different is which organization is asking now.
The VA Has Its Own Concerns
This is the part most coverage will skip. At the April committee hearing, VA officials expressed concerns about the bill.
That matters. The agency would be the one building the office, writing the standards and absorbing the step therapy change. An endorsement from outside does not resolve reluctance inside.
It is also not a contradiction. A VA official has already said the federal government needs to prepare for psychedelic medicine, as we reported at the time. Preparing and being mandated are different postures.
Why This Endorsement Carries Weight
The American Legion is one of the largest and most influential veterans service organizations in the country. Its resolutions function as a lobbying agenda.
Veterans advocacy has been the most effective force in this policy area for several years. The constituency is bipartisan, sympathetic and organized.
The scale of the underlying demand is not hypothetical either. RAND estimated that nearly 5 million veterans have already tried psychedelics, mostly outside any clinical setting.
What Clinics Should Watch
The credentialing language is the piece with the longest reach. If the VA writes workforce standards for psychedelic-assisted therapy, those standards become the reference point nationally.
Private practices do not have to follow VA rules. They will be compared to them anyway, by patients, by insurers and eventually by state boards.
Meanwhile the clinical work continues on its own track. The VA is already running a phase 3 psilocybin trial in veterans that reports in 2030.
The Bottom Line
A resolution is not a law. S.4220 has had one committee hearing and no floor vote, and the agency it would bind has reservations.
What changed is the coalition. A major veterans organization has put its lobbying weight behind a specific bill with specific machinery. That is different from endorsing the general idea that psychedelics deserve study.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical advice. Psilocybin, MDMA and ibogaine remain Schedule I substances under federal law and are not approved treatments.
